The safety and tolerability profiles for Imfinzi and the combination
of the drug with tremelimumab were consistent with previous trials,
the British drugmaker said. [nFWN2AY14Y]
Imfinzi is approved for patients with locally advanced or metastatic
bladder cancer previously treated with platinum-containing
chemotherapy in 15 countries, including the United States.
Imfinzi and tremelimumab belong to the immunotherapy class of
treatments, which strengthen the body's defenses to fight cancer and
tumors.
![](http://archives.lincolndailynews.com/2020/Mar/06/images/ads/current/holyfamily_lda_EASTER_2020.png)
[to top of second column] |
![](http://archives.lincolndailynews.com/2020/Mar/06/images/ads/current/Library_lda_EDUCATION_2020.png)
In 2018, about 550,000 people were diagnosed with bladder cancer around the
world and 200,000 died from the disease, AstraZeneca said.
Imfinzi is also being tested as a monotherapy and in combinations including with
tremelimumab, as a treatment for other forms of cancer, including head and neck,
liver and cervical.
(Reporting by Aakash Jagadeesh Babu in Bengaluru; editing by Uttaresh.V, Bernard
Orr)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |